{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:11Z","timestamp":1791216491150,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":951,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A 54-year old patient with metastatic melanoma presented with asymptomatic myositis and myocarditis after combined immune checkpoint inhibitors (ICI) therapy (anti-programmed cell death receptor-1, anti-lymphocyte activating gene-3, and anti-indoleamine 2,3-dioxygenase-1). The diagnosis was based on the typical time window after ICI, recurrence upon re-challenge, elevations of CK, high-sensitive troponin T (hs-TnT) and I (hs-TnI), mild NT-proBNP increase, and positive magnetic resonance imaging criteria. Notably, hsTnI was found to more rapidly increase and fall and to be more heart-specific than TnT in the context of ICI-related myocarditis. This led to ICI therapy withdrawal and switch to a less effective systemic therapy. This case report highlights the differential value of hs-TnT and hs-TnI for diagnosis and monitoring of ICI-related myositis and myocarditis.<\/jats:p>","DOI":"10.1002\/ehf2.14360","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T03:38:49Z","timestamp":1680752329000},"page":"2680-2685","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Value of Troponin T Versus I in the Diagnosis of Immune Checkpoint Inhibitor-Related Myocarditis and Myositis: Rechallenge?"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9235-6597","authenticated-orcid":false,"given":"Valentina A.","family":"Rossi","sequence":"first","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gawinecka","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florentia","family":"Dimitriou","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry, University Hospital Zurich and University of Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Ruschitzka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian M.","family":"Matter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Heart Center, University Hospital Zurich , Zurich ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"2026012114091225800_ehf214360-bib-0001","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026012114091225800_ehf214360-bib-0002","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012114091225800_ehf214360-bib-0003","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/cvr\/cvz026","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors","volume":"115","author":"Hu","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026012114091225800_ehf214360-bib-0004","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jacc.2017.05.062","article-title":"High-sensitivity cardiac troponin concentration and risk of first-ever cardiovascular outcomes in 154,052 participants","volume":"70","author":"Willeit","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2026012114091225800_ehf214360-bib-0005","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026012114091225800_ehf214360-bib-0006","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.118.007598","article-title":"Diagnostic performance of extracellular volume, native T1, and T2 mapping versus Lake Louise criteria by cardiac magnetic resonance for detection of acute myocarditis: a meta-analysis","volume":"11","author":"Pan","year":"2018","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026012114091225800_ehf214360-bib-0007","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ejca.2019.09.009","article-title":"A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies","volume":"124","author":"Guo","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026012114091225800_ehf214360-bib-0008","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/ejhf.2265","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114091225800_ehf214360-bib-0009","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026012114091225800_ehf214360-bib-0010","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026012114091225800_ehf214360-bib-0011","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2026012114091225800_ehf214360-bib-0012","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012114091225800_ehf214360-bib-0013","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s12885-019-5701-6","article-title":"Immune-related adverse events associated with programmed cell death protein-1 and programmed cell death ligand 1 inhibitors for non-small cell lung cancer: a PRISMA systematic review and meta-analysis","volume":"19","author":"Sun","year":"2019","journal-title":"BMC Cancer"},{"key":"2026012114091225800_ehf214360-bib-0014","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ahj.2013.07.004","article-title":"High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men","volume":"166","author":"Eggers","year":"2013","journal-title":"Am Heart J"},{"key":"2026012114091225800_ehf214360-bib-0015","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.amjcard.2016.06.043","article-title":"Gender, high-sensitivity troponin I, and the risk of cardiovascular events (from the Nord-Trondelag Health Study)","volume":"118","author":"Lyngbakken","year":"2016","journal-title":"Am J Cardiol"},{"key":"2026012114091225800_ehf214360-bib-0016","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"2026012114091225800_ehf214360-bib-0017","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1373\/jalm.2019.029785","article-title":"High-sensitivity cardiac troponin I and T kinetics after non-ST-segment elevation myocardial infarction","volume":"5","author":"van Doorn","year":"2020","journal-title":"J Appl Lab Med"},{"key":"2026012114091225800_ehf214360-bib-0018","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaccao.2022.11.004","article-title":"Biomarker trends, incidence, and outcomes of immune checkpoint inhibitor-induced myocarditis","volume":"4","author":"Vasbinder","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026012114091225800_ehf214360-bib-0019","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.122.061976","article-title":"Skeletal muscle disorders: a non-cardiac source of cardiac troponin T","volume":"146","author":"du Fay de Lavallaz","year":"2022","journal-title":"Circulation"},{"key":"2026012114091225800_ehf214360-bib-0020","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jaccao.2022.10.007","article-title":"Longitudinal strain and troponin I elevation in patients undergoing immune checkpoint inhibitor therapy","volume":"4","author":"Tamura","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026012114091225800_ehf214360-bib-0021","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"2026012114091225800_ehf214360-bib-0022","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1093\/ibd\/izy104","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","journal-title":"Inflamm Bowel Dis"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2680\/64704977\/eschf_10_4_2680.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/4\/2680\/64704977\/eschf_10_4_2680.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:09:48Z","timestamp":1769022588000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/4\/2680\/8285322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4,6]]},"published-print":{"date-parts":[[2023,8,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14360","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8]]},"published":{"date-parts":[[2023,4,6]]},"assertion":[{"value":"2023-01-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-05","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}